122 related articles for article (PubMed ID: 38030591)
1. Evaluation of the potential drug-drug interactions of carotegrast methyl with midazolam, prednisolone or atorvastatin in healthy adults.
Matsuki S; Oikawa I; Koyama T; Imai H
Br J Clin Pharmacol; 2024 Mar; 90(3):871-881. PubMed ID: 38030591
[TBL] [Abstract][Full Text] [Related]
2. Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study.
Imai H; Oikawa I; Koyama T; Matsuki S
Br J Clin Pharmacol; 2024 Jun; 90(6):1395-1407. PubMed ID: 38408756
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults.
Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuzaki T; Matsuo Y; Kubota R
Clin Drug Investig; 2023 May; 43(5):335-346. PubMed ID: 37171749
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
5. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
Adeloye T; Sahgal O; Puri A; Warrington S; Endo T; Dennison J; Johnston A
Clin Pharmacol Drug Dev; 2018 Nov; 7(8):844-859. PubMed ID: 30044899
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.
Townsend R; Dietz A; Hale C; Akhtar S; Kowalski D; Lademacher C; Lasseter K; Pearlman H; Rammelsberg D; Schmitt-Hoffmann A; Yamazaki T; Desai A
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):44-53. PubMed ID: 27273461
[TBL] [Abstract][Full Text] [Related]
7. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
Hoch M; Hoever P; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
[TBL] [Abstract][Full Text] [Related]
8. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
de Jong J; Mitselos A; Jurczak W; Cordoba R; Panizo C; Wrobel T; Dlugosz-Danecka M; Jiao J; Sukbuntherng J; Ouellet D; Hellemans P
Pharmacol Res Perspect; 2020 Oct; 8(5):e00649. PubMed ID: 32945596
[TBL] [Abstract][Full Text] [Related]
12. A Physiologically Based Pharmacokinetic Modeling Approach to Assess the Potential for Drug Interactions Between Trofinetide and CYP3A4-Metabolized Drugs.
Darwish M; Youakim JM; Darling I; Lukacova V; Owen JS; Bradley H
Clin Ther; 2024 Mar; 46(3):194-200. PubMed ID: 38307724
[TBL] [Abstract][Full Text] [Related]
13. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.
Syed S; Clemens PL; Lathers D; Kollia G; Dhar A; Walters I; Masson E
J Clin Pharmacol; 2012 Jun; 52(6):914-21. PubMed ID: 21659627
[TBL] [Abstract][Full Text] [Related]
15. A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver.
Kumagai Y; Fujita T; Maeda M; Sasaki Y; Nagaoka M; Huang J; Takenaka T; Kawai M
J Clin Pharmacol; 2020 Jun; 60(6):702-710. PubMed ID: 32026490
[TBL] [Abstract][Full Text] [Related]
16. The Effect of GS-548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS-6637 in Healthy Adults.
Bunn HT; Rosenthal E; Mathur P; McLaughlin M; Proschan M; Vijan A; Aepfelbacher J; Kottilil S; Masur H; Kattakuzhy S; George JM
J Clin Pharmacol; 2020 Dec; 60(12):1598-1605. PubMed ID: 32578227
[TBL] [Abstract][Full Text] [Related]
17. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Guo J; Zhou D; Li Y; Khanh BH
Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
[TBL] [Abstract][Full Text] [Related]
18. Food Effect on a Single High Dose of Carotegrast Methyl, an Oral Antagonist of α4-Integrin, in Healthy Male Subjects: A Randomised, Placebo-Controlled, Double-Blind Study.
Fukase H; Kajioka T; Oikawa I; Ikeda N; Furuie H
Clin Drug Investig; 2020 Mar; 40(3):237-247. PubMed ID: 31965548
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects.
Winter H; Egizi E; Erondu N; Ginsberg A; Rouse DJ; Severynse-Stevens D; Pauli E; Everitt D
Antimicrob Agents Chemother; 2013 Aug; 57(8):3699-703. PubMed ID: 23689718
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
